Effect of heparin on production of basic fibroblast growth factor and transforming growth factor-beta1 by human normal skin and hyperplastic scar fibroblasts

Journal of Burn Care and Research

Volumn 28, Issue 5, 2007, Pages 734-741

  Fan, Shu Qiang ^a,b   Qin, Li Yan ^c   Cai, Jing Long ^a   Zhu, Gui Ying ^a   Bin, Xu ^a   Yan, Hong Shan ^a  

^a SHANDONG UNIVERSITY   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c SHANDONG JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; HEPARIN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CLINICAL RESEARCH; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM HYPERPLASIA; EXTRACELLULAR MATRIX; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SCAR FORMATION; SKIN CULTURE; STATISTICAL SIGNIFICANCE; SUPERNATANT; WOUND HEALING;

ADULT; CICATRIX; COLLAGEN; FIBROBLAST GROWTH FACTORS; FIBROBLASTS; HEPARIN; HUMANS; HYPERPLASIA; SKIN; TRANSFORMING GROWTH FACTOR BETA1; WOUND HEALING;

EID: 34548835480     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0B013E318148C9D0     Document Type: Article

References (71)

1. Cavari S, Ruggiero M, Vannucchi S. Antiproliferative effects of heparin on normal and transformed NIH/3T3 fibroblasts. Cell Biol Int 1993;17:781-6.
2. Ferrao AV, Mason RM. The effect of heparin on cell proliferation and type-I collagen synthesis by adult human dermal fibroblasts. Biochim Biophys Acta 1993;1180:225-30.
3. San Antonio JD, Lander AD, Wright TC, et al. Heparin inhibits the attachment and growth of Balb/c-3T3 fibroblasts on collagen substrata. J Cell Physiol 1992;150:8-16.
4. Striker LJ, Peten EP, Elliot SJ, et al. Mesangial cell turnover: effect of heparin and peptide growth factors. Lab Invest 1991;64:446-56.
5. Wever J, Schachtschabel DO, Sluke G, et al. Effect of short-or longterm treatment with exogenous glycosaminoglycans on growth and glycosaminoglycan synthesis of human fibroblasts (WI-38) in culture. Mech Ageing Dev 1980;14:89-99.
6. Asselot C, Labat-Robert J, Kern P. Heparin fragments regulate collagen phenotype and fibronectin synthesis in the skin of genetically diabetic mice. Biochem Pharmacol 1989;38:895-9.
7. el Nabout R, Martin M, Remy J, et al. Heparin fragments modulate the collagen phenotype of fibroblasts from radiation-induced subcutaneous fibrosis. Exp Mol Pathol 1989;51:111-22.
8. Tan EM, Peltonen J. Endothelial cell growth factor and heparin regulate collagen gene expression in keloid fibroblasts. Biochem J 1991;278:863-9.
9. Gospodarowicz D, Neufeld G, Schweigerer L. Fibroblast growth factor. Mol Cell Endocrinol 1986;46:187-204.
10. Buckley-Sturrock A, Woodward SC, Senior RM, et al. Differential stimulation of collagenase and chemotactic activity in fibroblasts derived from rat wound repair tissue and human skin by growth factors. J Cell Physiol 1989;138:70-8.
11. Tan EM, Rouda S, Greenbaum SS, et al. Acidic and basic fibroblast growth factors down-regulate collagen gene expression in keloid fibroblasts. Am J Pathol 1993;142:463-70.
12. Pierce GF, Tarpley JE, Yanagihara D, et al. Platelet-derived growth factor (BB homodimer), transforming growth factor-beta 1, and basic fibroblast growth factor in dermal wound healing: neovessel and matrix formation and cessation of repair. Am J Pathol 1992;140:1375-88.
13. Robson MC. The role of growth factors in the healing of chronic wounds. Wound Rep Reg 1997;5:12-7.
14. Assagué J 1990. The transforming growth factor-β family. Annu Rev Cell Biol 6:597.
15. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994;331:1286.
16. Miyazono K, ten Dijke P, Heldin CH. TGF-β signaling by Smad proteins. Adv Immunol 2000;75:115.
17. Hong RH, Lum J, Koch RJ. Growth of keloid-producing fibroblasts in commercially available serum-free media. Otolaryngol Head Neck Surg 1999;121:468-73.
18. Castellot JJ, Addonizio ML, Rosenberg RD, et al. Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle cell growth. J Cell Bio1 1981;90:372-9.
19. Reilly CF, Fritze LMS, Rosenberg RD. Heparin inhibition of smooth muscle cell proliferation: a cellular site of action. J Cell Physiol 1986;129:11-9.
20. Vannuchi S, Pasquali F, Fiorelli G, et al. Effect of heparin on proliferation and signalling in BC3H-1 muscle cells. FEBS lett 1990;263:137-41.
21. Herbert JM, Maffrund JP. Heparin interactions with cultured human vascular endothelial and smooth muscle cells: incidence on vascular smooth muscle proliferation. J Cell Physiol 1989;138:424-32.
22. Vannuchi S, Pasquali F, Chiarugi V, et al. Internalization and metabolism of endogenous heparin by cultured endothelial cells. Biochem Biophys Res Commun 1986;140:294-301.
23. Schaffrath D, Stahlsatz HW, Greiling H. Interactions of glycosaminoglycans with DNA and RNA synthesizing enzymes in vitro. Hoppe-Seylers Z Physiol Chem 1976;357:499-508.
24. Kitamura M, Maruyama N, Mitarai T, et al. Heparin selectively inhibits gene expression of matrix metalloproteinase transin in cultured mesangial cells. Biochem Biophys Res Commun 1994;203:1333-8.
25. Gosh TK, Eis PS, Mullaney JM, et al. Competitive, reversible, and potent antagonism of Inositol 1,4,5-triphosphate-activated calcium release by heparin. J Biol Chem 1988;263:11075-9.
26. Smith CD, Wen D, Mooberry SL, et al. Inhibition of phosphatidylinositol- 4-phosphate by heparin. Biochem J 1990;109:441-8.
27. Bennett MR, Littlewood TL, Hancock DC, et al. Down-regulation of the c-myc proto-oncogene in inhibition of vascular smooth-muscle cell proliferation: a signal for growth arrest? Biochem J 1994;302:701-8.
28. Pukac LA, Castellot JJ, Wright TC, et al. Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells. J Biol Chem 1992;267:3707-11.
29. Reilly CR, Kindy MS, Brown KE, et al. Heparin prevents vascular smooth muscle progression through the G1 phase of the cell cycle. J Biol Chem 1989;264:6990-5.
30. Wright RC, Pukac LA, Catellot JJ, et al. Heparin suppresses the induction of c-fos and c-myc mRNA in murine fibroblasts by selective inhibition of a protein kinase c-dependent pathway. Proc Natl Acad Sci USA 1989;86:3199-203.
31. Yamada KM, Kennedy DW, Kimata K, et al. Characterization of fibronectin interactions with glycosaminoglycans and identification of active proteolytic fragments. J Biol Chem 1980;255:6055-63.
32. Sakashita S, Engvall E, Ruoslahti E. Basement membrane glycoprotein laminin binds to heparin. FEBS Lett 1980;116:243-6.
33. Lawler J, Slayter H. The release of heparin binding peptides from platelet thrombospondin by proteolytic action of thrombin, plasmin, and trypsin. Thromb Res 1981;22:267-79.
34. Keller KM, Keller JM, Kuhn K. The c-terminus of type I collagen is a major bidning site for heparin. Biochim Biophys Acta 1986;882:1-5.
35. Tsilibary EC, Reger LA, Vogel AM, et al. Identification of a multifunctional, cell-binding peptide sequence from the a1(NC1) of type IV collagen. J Cell Biol 1990;111:1583-91.
36. Ignotz RA, Massague J. Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-beta. J Biol Chem 1987;262:6443-7.
37. Moulin V. Growth factors in skin wound healing. Eur J Cell Biol 1995;68:1-7.
38. Krummel TM, Michna BA, Thomas BL, et al. Transforming growth factor beta (TGF-beta) induces fibrosis in a fetal wound model. J Pediatr Surg 1988;23:647-52.
39. Lin RY, Sullivan KM, Argenta PA, et al. Exogenous transforming growth factor-beta amplifies its own expression and induces scar formation in a model of human fetal skin repair. Ann Surg 1995;222:146-54.
40. Shah M, Foreman DM, Ferguson MW. Neutralization of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995;108:985-1002.
41. Tsuboi R, Rifkin DB. Recombinant basic fibroblast growth factor stimulates wound healing in healing-impaired db/db mice. J Exp Med 1990;172:245-51.
42. Klagsbrun M. Mediators of angiogenesis: the biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions. Cancer Biol 1992;3:81-7.
43. Maciag T, Melman T, Friesel R, et al. Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain. Science 1984;225:932-5.
44. Shing Y, Folkman J, Sullivan R, et al. Heparin affinity: Purification of a tumor-derived capillary endothelial cell growth factor. Science 1984;223:1296-9.
45. Gospodarowicz D, Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 1986;128:475-84.
46. Coltrini D, Rusnati M, Zoppetti G, et al. Biochemical bases of the interaction of human basic fibroblast growth factor with glycosaminoglycans. New insights from trypsin digestion studies. Eur J Biochem 1993;214:51-8.
47. Lobb RR. Thrombin inacrtivates acidic fibroblast growth factor but not basic fibroblast growth factor. Biochemistry 1988;27:2572-8.
48. Rosengart TK, Johnson WV, Friesel R, et al. Heparin protects heparin-binding growth factor-I from proteolytic inactivation in vitro. Biochem Biophys Res Commun 1988;152:432-40.
49. Sommer A, Rifkin DB. Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J Cell Physiol 1989;138:215-20.
50. Moscatelli D, Sommer A, Rifkin DB. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988;107:743-51.
51. Saksela O, Moscatelli D, Sommer A, et al. Endothelial cellderived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988;107:743-51.
52. Nissen NN, Shankar R, Gamelli RL, et al. Heparin and heparan sulphate protect basic fibroblast growth factor from nonenymic glucosylation. Biochem J 1999;338:637-42.
53. Ruoslahti E, Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell 1991;64:867-9.
54. Ishai-Michaeli R, Eldor A, Vlodavsky I. Heparanase activity expressed by platelets, neutrophils, and lymphoma cell releases active fibroblast growth factor from extracellular matrix. Cell Regul 1990;1:833-42.
55. Saksela O, Rifkin DB. Release of basic fibroblast growth factorheparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 1990;110:767-75.
56. Brown KJ, Hendry IA, Parish CR. Acidic and basic fibroblast growth factor bind with differing affinity to the same heparin sulfate proteoglycan on BALB/c3T3 cells: implications for potentiation of growth factor action by heparin. J Cell Biochem 1995;58:6-14.
57. Spivak-Kroizman T, Lemmon MA, Dikic I, et al. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 1994;79:1015-24.
58. Yayon A, Klagsbrun M, Esho JD, et al. Cell surface, heparin-like molecules are required from binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991;64:841-8.
59. Faham S, Hileman RE, Fromm JR, et al. Heparin structure and interactions with basic fibroblast growth factor. Science 1996;271:1116-20.
60. Andres JL, Stanley K, Cheifetz S, et al. Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoplycan that bind transforming growth factor-beta. J Cell Biol 1989;109:3137-45.
61. Lyon M, Rushton G, Gallagher JT. The interaction of the transforming growth factor-betas with heparin/heparan sulfate is isoform specific. J Biol Chem 1997;272:18000-6.
62. McCaffrey TA, Falcone DJ, Vincente D, et al. Protection of transforming growth factor-beta 1 activity by heparin and fucoidan. J Cell Physiol 1994;159:51-9.
63. Yard BA, Chorianopoulos E, Herr D, et al. Regulation of endothelin- 1 and transforming growth factor-beta 1 production in cultured proximal tubular cells by albumin and heparan sulfate glycosaminoglycans. Nephrol Dial Transplant 2001;16:1769-75.
64. McCaffrey TA, Falcone DJ, Brayton CF, et al. Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex. J Cell Biol 1989;109:441-8.
65. McCaffrey TA, Falcone DJ, Borth W, et al. Alpha 2-macroglobulin/ transforming growth facto-beta 1 interactions. Modulation by heparin-like molecules and effects on vascular smooth muscle cells. Ann New York Acad Sci 1994;737:368-82.
66. Cheifetz S, Like B, Massague J. Cellular distributrion of type I and type II receptors for transforming growth factor-beta. J Biol Chem 1986;261:9972-8.
67. Raghow R, Postlethwaite AE, Keski-Oja J, et al. Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest 1987;79:1285-8.
68. Bonewald LF. Regulation and regulatory activities of transforming growth factor beta. Crit Rev Eukaryot Hene Expr 1999;9:33-44.
69. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-91.
70. Mangasser-Stephan K, Gressner AM. Molecular and functional aspects of latent transforming growth-factor beta binding protein: just a masking protein? Cell Tissue Res 1999;297:363-70.
71. Hildebrand A, Romaris M, Rasmussen LM, et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 1994;302:527-34.